HistoSonics has developed a non-invasive, sonic beam therapy platform that uses histotripsy, which is capable of destroying targeted liver tumors at a sub-cellular level.

HistoSonics

HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy.  Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels.  The company’s new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities.  HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.

Yonjin Venture

Johnson & Johnson Innovation – JJDC

Venture Investors

Lumira Ventures

State of Wisconsin Investment Board

Signature Bank

Varian

Johnson & Johnson Robotics and Digital Solutions

Fred Moll, M.D

HealthQuest Capital

Alpha Wave Ventures

Amzak Health Investors

HistoSonics, Inc.

HistoSonics, Inc. appreciates the Nasdaq for promoting our $102M Series D financing news today. Thanks to Alpha Wave Global , a world leader in growth stage investments, who led the round with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation JJDC Inc, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Yonjin Venture, the State of Wisconsin Investment Board, and others. 

#HistoSonics #Histotripsy #Nasdaq

HistoSonics, Inc. appreciates the NYSE for promoting our $102M Series D financing news today. Thanks to Alpha Wave Global , a world leader in growth stage investments, who led the round with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation JJDC Inc, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Yonjin Venture, the State of Wisconsin Investment Board, and others. 

#HistoSonics #Histotripsy #NYSE

HistoSonics, Inc. is honored to announce the completion of an oversubscribed $102 million Series D financing which will be used to accelerate category defining advancements to our non-invasive histotripsy platforms, support commercial growth in the US and in planned global markets, and initiate the company’s innovative, prospective BOOMBOX Master Study. The round was led by Alpha Wave Global, a world leader in growth stage investments, with participation from new investors Amzak Capital Management and HealthQuest Capital, and existing investors Johnson & Johnson Innovation JJDC Inc, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Yonjin Venture, the State of Wisconsin Investment Board, and others.

We are excited to have such experienced investors join our team at HistoSonics, and whose investment reinforces our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types. 


#TeamHisto #Histotripsy #MinimallyInvasiveneIsntMinimalEnough




https://lnkd.in/gZy6W9qK

HistoSonics, Inc. is honored to be nominated for a 2024 Prix Galien Award, the United States’ preeminent prize acknowledging the leading-edge of scientific advances in life sciences. Our entire team shares pride in being nominated for this prestigious award and for our conintinuing partnership with innovative scientists and physicians to provide meaningful change for patients suffering from disease.  We look forward to both the Prix Galien Forum and Awards in NYC on November 7th, 2024.

#Histotripsy #HistoSonics #InnovationMatters #PrixGalien

https://lnkd.in/ev2cTc29

HistoSonics, Inc. is extremely proud to collaborate with Tawam Hospital, SEHA leadership, and the Tawam clinical team led by senior Surgical Oncologist Dr Philipp August Von Breitenbuch as our first global program partner to acquire and treat patients with the Edison Histotripsy System. Our shared mission to provide innovative, meaningful care to patients suffering with liver tumors in the UAE and around the world has been realized through Tawam Hospital successfully treating their initial patients with non-invasive histotripsy. We look forward to continuing our partnership with Tawam Hospital and SEHA leadership to provide the best care possible for patients across the UAE and globally.

#PartnersInInnovation #Histotripsy #HistoSonics #SEHA


The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

One of the most unique traditions at HistoSonics, Inc. is for our entire team to take the week of Independence Day off from work to be with family and friends, and to enjoy celebrating the Holiday with those we love. 2024 was no different and we have so many wonderful examples of our Histo Team creating lasting memories around the world. Thank you to our entire Histo Team for a great first half of 2024, especially those that continued to support our clinical partners and patients over the Holiday. 
We look forward to continuing the great momentum we have in 2024 and to bringing meaningful change to as many patients and their families as possible!
#TeamHisto  #MinimallyInvasiveIsntMinimalEnough #Family

Breaking News @ HistoSonics, Inc.: UNOS Adds Histotripsy As An Additional Therapy Option for Liver Transplant Candidates with Primary Liver Tumors 

The United Network for Organ Sharing (UNOS) announced that beginning July 25, 2024, the OPTN (Organ Procurement and Transplantation Network) Waiting List will be updated by adding ‘histotripsy’ as an additional loco-regional therapy option for initial and extension exception requests for liver candidates with primary liver tumors. 

The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

The #2024SRS meeting, in Orlando, begins this Thursday June 20th and HistoSonics, Inc. looks forward to kicking off Day 1 of SRS by participating in executive panel discussions as part of MedTech Investor Day. 
We also invite the world's leading surgeon innovators and attendees to "Meet Edison" for hands-on demonstrations at our booth where you can target, plan and deliver non-invasive histotripsy with the Edison System to liquefy tissue in real time. 

#BubblesAreChangingEverything #Histotripsy #MinimallyInvasiveIsntMinimalEnough

HistoSonics, Inc. is excited to have a strong presence at the upcoming #2024SRS meeting, in Orlando, June 20th-23rd. Surgeons currently utilizing histotripsy to non-invasively destroy tumors in both the liver and kidney will be presenting their experiences using the Edison Histotripsy System. Also, members of our HistoSonics leadership team will participate in panel discussions to describe histotripsy's unique mechanism of action and how we see histotripsy impacting the future of surgery. 

We invite the world's leading surgeon innovators and attendees at #SRS2024 to "Meet Edison" for hands-on demonstrations at our booth #B105, and hope to see you in the many histotripsy sessions.

#MeetEdison #HistoSonics #MinimallyInvasiveIsntMinimalEnough

HistoSonics, Inc. is looking forward to demonstrating our Edison Histotripsy System at the American Transplant Congress (ATC) in Philadelphis June 1st - 4th. 
Please stop by our Booth 725 or our Tech Suite MR2 on the exhibition floor to get hands on demonstrations and liquefy targeted tumor models with the Edison System now FDA cleared to non-invasively destroy targeted liver tumors. Stop by to see our experts and discuss the innovative use of histotripsy by transplant and hepatobiliary surgeons.
#MinimallyInvasiveIsntMinimalEnough #HistoSonics #Histotripsy

Metric
Company Name	HistoSonics
Symbol
MSH ID	COM:HISTOSONICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Technology
Country	US
Stage
Employee Count
Website	histosonics.com
LinkedIn	histosonics-inc-
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:HISTOSONICS

HistoSonics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue